Manuscripts
Showing 1530 manuscripts.
Influence of NAT2 genotype and maturation on isoniazid exposure in low-birth-weight and preterm infants with or without HIV exposure
Citation
Agathe Béranger, Adrie Bekker, Belén P. Solans, Mark F. Cotton, Mark Mirochnick, Avy Violari, Jiajia Wang, Mae Cababasay, Lubbe Wiesner, Renee Browning, Jack Moye, Edmund V. Capparelli, Radojka M. Savic. Influence of NAT2 genotype and maturation on isoniazid exposure in low-birth-weight and preterm infants with or without HIV exposure. Clinical Infectious Diseases. 2022. PMID: 35134861
Year
Journal
Study
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Citation
J Lommerse, D Clarke, T Kerbusch, H Merdjan, H Witjes, H Teppler, M Mirochnick, EP Acosta, L Wenning, S Nachman, A Chain. Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing. CPT: pharmacometrics & systems pharmacology. 2019. 8: 643-653. PMID: 31215170
Journal
Study
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial
Citation
Ashenafi S Cherkos, Sylvia M LaCourse, Daniel A Enquobahrie, Barbra A Richardson, Sarah Bradford, Grace Montepiedra, Blandina T Mmbaga, Tapiwa Mbengeranwa, Gaerolwe Masheto, Patrick Jean-Phillippe, Nahida Chakhtoura, Gerhard Theron, Adriana Weinberg, Haseena Cassim, Mpho S Raesi, Elsie Jean, Deo Wabwire, Teacler Nematadzira, Lynda Stranix-Chibanda, Anneke C Hesseling, Linda Aurpibul, Amita Gupta, Grace John-Stewart, IMPAACT P1078 TB APPRISE Study Team. Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial. eClinicalMedicine. 2023. 58: 101912. PMID: 36969345
Year
Journal
Study
Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term
Citation
Ceejay L. Boyce, Ingrid A. Beck, Sheila M. Styrchak, Samantha R. Hardy, Jackson J. Wallner, Ross S. Milne, R. Leavitt Morrison, David Shapiro, Esaú C João, Mark Mirochnick, Lisa M. Frenkel. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term. PLoS One. 2022. 17: e0275254. PMID: 36166463
Year
Journal
Study
Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081
Citation
Conrado Milani Coutinho, Meredith G. Warshaw, Geraldo Duarte, Alice Stek, Avy Violari, Cristina B. Hofer, Jaime G. Deville, James Samwel Ngocho, José Henrique Pilotto, Mario Dias Correa Jr., David E. Shapiro, Trevon L. Fuller, Nahida Chakhtoura, Mark Mirochnick, Esaú C. João. Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081. Journal of Acquired Immune Deficiency Syndromes. 2022. 91: 403-409. PMID: 36049477
Year
Journal
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
Citation
Christine E MacBrayne, Richard M Rutstein, Andrew A Wiznia, Bobbie Graham, Carmelita G Alvero, Lee Fairlie, Kathryn Lypen, Kathleen H George, Ellen Townley, Jack Moye Jr., Diane G Costello, Christina A Reding, Cristina Barroso Hofer, Herta M Crauwels, Xavier Woot de Trixhe, Lotke Tambuyzer, Simon Vanveggel, Magda Opsomer, Jennifer J Kiser, IMPAACT P1090 Protocol Team. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. AIDS. 2021. 35: 1413-1421. PMID: 33831904
Year
Journal
Study
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
Citation
Stein Schalkwijk, Rob Ter Heine, Angela C Colbers, Alwin D R Huitema, Paolo Denti, Kelly E Dooley, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, Mark Mirochnick, David M Burger. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clinical Pharmacokinetics. 2018. 57: 1421-1433. PMID: 29520730
Year
Journal
Study
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling
Citation
Stein Schalkwijk, Rob Ter Heine, Angela Colbers, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, José Moltó, Mark Mirochnick, Mats O Karlsson, David M Burger. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy. 2019. 74: 1348-1356. PMID: 30715324
Year
Journal
Study
Darunavir Pharmacokinetics With an Increased Dose During Pregnancy
Citation
Ahizechukwu C Eke, Alice M Stek, Jiajia Wang, Regis Kreitchmann, David E Shapiro, Elizabeth Smith, Nahida Chakhtoura, Edmund V Capparelli, Mark Mirochnick, Brookie M Best, IMPAACT P1026s Protocol Team. Darunavir Pharmacokinetics With an Increased Dose During Pregnancy. Journal of Acquired Immune Deficiency Syndromes. 2020. 83: 373-380. PMID: 31923087
Year
Journal
Study
Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate
Citation
Ahizechukwu C Eke, Kensuke Shoji, Brookie M Best , Jeremiah D Momper, Alice M Stek, Tim R Cressey, Mark Mirochnick, Edmund V Capparelli. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. Antimicrobial Agents and Chemotherapy. 2021. 65: e02168-20. PMID: 33318014